Uniqure (QURE) Stock Price Up 8.2%

Uniqure NV (NASDAQ:QURE) rose 8.2% during trading on Thursday . The company traded as high as $61.99 and last traded at $61.18. Approximately 938,368 shares were traded during mid-day trading, an increase of 81% from the average daily volume of 517,352 shares. The stock had previously closed at $56.52.

QURE has been the subject of a number of research reports. Chardan Capital raised their price target on shares of Uniqure from $50.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, November 7th. HC Wainwright set a $48.00 price objective on shares of Uniqure and gave the company a “buy” rating in a research note on Wednesday, November 7th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $65.00 price objective on shares of Uniqure in a research note on Thursday, November 15th. B. Riley began coverage on shares of Uniqure in a research note on Monday, December 31st. They issued a “buy” rating and a $72.00 price objective on the stock. Finally, Guggenheim began coverage on shares of Uniqure in a research note on Monday, December 17th. They issued a “buy” rating and a $35.00 price objective on the stock. One research analyst has rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Uniqure presently has a consensus rating of “Buy” and an average target price of $66.20.

The company has a debt-to-equity ratio of 0.05, a current ratio of 7.56 and a quick ratio of 7.56.

Uniqure (NASDAQ:QURE) last released its quarterly earnings results on Thursday, February 28th. The biotechnology company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.08. Uniqure had a negative net margin of 725.04% and a negative return on equity of 58.49%. Sell-side analysts forecast that Uniqure NV will post -2.9 earnings per share for the current fiscal year.

In related news, SVP Alexander Edward Kuta III sold 8,000 shares of the firm’s stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $35.82, for a total transaction of $286,560.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Matthew C. Kapusta sold 19,085 shares of the firm’s stock in a transaction dated Monday, January 28th. The shares were sold at an average price of $31.42, for a total transaction of $599,650.70. Following the transaction, the chief executive officer now directly owns 490,028 shares in the company, valued at $15,396,679.76. The disclosure for this sale can be found here. Insiders have sold 46,014 shares of company stock worth $1,454,779 over the last three months. 1.56% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California Public Employees Retirement System lifted its position in shares of Uniqure by 101.3% during the second quarter. California Public Employees Retirement System now owns 28,427 shares of the biotechnology company’s stock valued at $1,075,000 after purchasing an additional 14,307 shares in the last quarter. Allianz Asset Management GmbH raised its position in Uniqure by 9.4% in the third quarter. Allianz Asset Management GmbH now owns 54,332 shares of the biotechnology company’s stock worth $1,977,000 after acquiring an additional 4,679 shares during the period. Wells Fargo & Company MN raised its position in Uniqure by 24.2% in the third quarter. Wells Fargo & Company MN now owns 17,829 shares of the biotechnology company’s stock worth $649,000 after acquiring an additional 3,472 shares during the period. Oppenheimer & Co. Inc. bought a new stake in Uniqure in the third quarter worth about $279,000. Finally, Northern Trust Corp bought a new stake in Uniqure in the second quarter worth about $602,000. 58.64% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.com-unik.info/2019/03/07/uniqure-qure-stock-price-up-8-2.html.

About Uniqure (NASDAQ:QURE)

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

See Also: Return on Investment (ROI) Defined, Explained

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit